Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HIMS
SellSinkerHims & Hers Health, Inc. · Healthcare · United States · $6.7B · Avg Vol: $354M/d
COMPANY DESCRIPTION
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform providing personalized health and wellness products and services directly to consumers, including prescription medications for conditions like hair loss, sexual health, and mental well-being. The company leverages a digital-first, subscription-based model to increase access to affordable healthcare solutions. Its competitive advantage is driven by its strong brand, user-friendly platform, and comprehensive product offerings in a rapidly expanding telehealth market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 526.9M | 872.0M | 1.5B | 2.3B | 64.5% | 2.6B | 3.2B | 4.0B | 30.4% |
| EPS | -0.32 | -0.11 | 0.58 | 0.57 | -1.7% | -0.64 | -0.55 | 0.44 | -12.5% |
| Shares | 208.4M | 213.5M | 220.8M | 227.2M | +9.0% | 224.9M | — | — | — |
| Debt | 5.3M | 9.9M | 11.3M | 1.1B | 495.5% | 1.5B | — | — | — |
| Equity | 311.7M | 344.0M | 476.7M | 540.9M | 20.2% | — | — | — | — |
| Op CF | -26.5M | 73.5M | 251.1M | 300.0M | 102.1% | 263.4M | — | — | — |
| Inv CF | 34.7M | -12.1M | -19.0M | -1.0B | — | — | — | — | — |
| Fin CF | -33.1M | -11.5M | -107.8M | 729.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HIMS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HIMS | Hims & Hers Health, Inc.(you) | $6.7B | 26 | Sell |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.9B | 30 | Sell |
| HROW | Harrow, Inc. | $1.5B | 29 | Sell |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.5B | 43 | Hold |
| LQDA | Liquidia Corporation | $6.1B | 64 | Hold |
| CURA.TO | Curaleaf Holdings, Inc. | $2.6B | 48 | Hold |
| GLAS | Glass House Brands Inc. | $931M | 18 | Strong Sell |
| ELAN | Elanco Animal Health Incorporated | $12.0B | 70 | Buy |
| VREO.CN | Vireo Growth Inc. | $552M | 33 | Sell |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.1B | 83 | Strong Buy |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%